KRAS-IN-54 is a macrocyclic KRAS inhibitor. KRAS-IN-54 exhibits activity against cell viability and pERK inhibition in cells with KRAS G12D and KRAS G13D mutations. KRAS-IN-54 can be used in the research of KRAS-mutant cancers, including pancreatic adenocarcinoma, colorectal cancer , non-small cell lung cancer , esophageal cancer , gallbladder cancer , melanoma, ovarian cancer and endometrial cancer .
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > PERK | Products > Signaling Pathways > Ras
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.